Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | peroxisome proliferator-activated receptor alpha | Starlite/ChEMBL | References |
Homo sapiens | peroxisome proliferator-activated receptor gamma | Starlite/ChEMBL | References |
Homo sapiens | peroxisome proliferator-activated receptor delta | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma mansoni | nuclear hormone receptor superfamily protein-related | Get druggable targets OG5_137778 | All targets in OG5_137778 |
Schistosoma japonicum | IPR008946,Nuclear receptor, ligand-binding,domain-containing | Get druggable targets OG5_137778 | All targets in OG5_137778 |
Schistosoma japonicum | ko:K08701 nuclear receptor, subfamily 1, invertebrate, putative | Get druggable targets OG5_137778 | All targets in OG5_137778 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | ecdysone induced protein 78C | peroxisome proliferator-activated receptor gamma | 477 aa | 447 aa | 28.2 % |
Brugia malayi | ecdysteroid receptor | peroxisome proliferator-activated receptor alpha | 468 aa | 397 aa | 25.4 % |
Brugia malayi | ecdysteroid receptor | peroxisome proliferator-activated receptor delta | 441 aa | 369 aa | 24.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | peptidase, M28 family protein | 0.0037 | 0 | 0.5 |
Leishmania major | glutaminyl cyclase, putative | 0.0037 | 0 | 0.5 |
Trichomonas vaginalis | Clan MH, family M28, aminopeptidase S-like metallopeptidase | 0.0037 | 0 | 0.5 |
Mycobacterium ulcerans | lipoprotein aminopeptidase LpqL | 0.0037 | 0 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0037 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0037 | 0 | 0.5 |
Echinococcus multilocularis | glutaminyl peptide cyclotransferase | 0.0235 | 0.5011 | 1 |
Trypanosoma cruzi | glutaminyl cyclase, putative | 0.0037 | 0 | 0.5 |
Mycobacterium tuberculosis | Conserved protein | 0.0037 | 0 | 0.5 |
Brugia malayi | Peptidase family M28 containing protein | 0.0235 | 0.5011 | 1 |
Echinococcus granulosus | glutaminyl peptide cyclotransferase | 0.0235 | 0.5011 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0235 | 0.5011 | 1 |
Mycobacterium tuberculosis | Probable lipoprotein aminopeptidase LpqL | 0.0037 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0037 | 0 | 0.5 |
Onchocerca volvulus | Glutaminyl cyclase homolog | 0.0235 | 0.5011 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0037 | 0 | 0.5 |
Trypanosoma brucei | glutaminyl cyclase, putative | 0.0037 | 0 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.0037 | 0 | 0.5 |
Schistosoma mansoni | glutaminyl cyclase (M28 family) | 0.0235 | 0.5011 | 0.5011 |
Leishmania major | hypothetical protein, conserved | 0.0037 | 0 | 0.5 |
Trypanosoma cruzi | glutaminyl cyclase, putative | 0.0037 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | = 0.05 uM | Agonist activity at human PPARdelta ligand binding domain expressed in human 293T cells co-transfected with Gal4-DBD by luciferase transactivation assay | ChEMBL. | 19928766 |
EC50 (binding) | > 10 uM | Agonist activity at human PPARalpha ligand binding domain expressed in human 293T cells co-transfected with Gal4-DBD by luciferase transactivation assay | ChEMBL. | 19928766 |
EC50 (binding) | > 10 uM | Agonist activity at human PPARgamma ligand binding domain expressed in human 293T cells co-transfected with Gal4-DBD by luciferase transactivation assay | ChEMBL. | 19928766 |
Efficacy (binding) | = 83 % | Agonist activity at human PPARdelta ligand binding domain expressed in human 293T cells co-transfected with Gal4-DBD by luciferase transactivation assay relative to GW-501516 | ChEMBL. | 19928766 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.